Single Patient Access (Compassionate Use) for Continued Treatment of RO7070179 for Adult Subjects With Advanced Hepatocellular Carcinoma (HCC)
| Status: | Available |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Contact: | Jennifer Wu, MD |
| Email: | Jennifer.Wu@nyumc.org |
| Phone: | 212-263-6485 |
This is a single-patient access (also referred to as Compassionate Use) setting for a patient
who has been treated and benefited from RO7070179 while participating in a clinical study of
RO7070179. The patient will receive the dose of RO7070179 at 6 mg/kg/week by IV infusion.
Treatment cycles will be defined as 42 (6 weeks) days.
who has been treated and benefited from RO7070179 while participating in a clinical study of
RO7070179. The patient will receive the dose of RO7070179 at 6 mg/kg/week by IV infusion.
Treatment cycles will be defined as 42 (6 weeks) days.
Inclusion Criteria:
1. Signed Informed Consent Form
2. Ability to comply with the protocol, in the investigator's judgment
3. Diagnosis of hepatocellular carcinoma based on previous biopsy
4. Previously treated with RO7070179 and demonstrated a clinical benefit
Exclusion Criteria: N/A
We found this trial at
1
site
New York, New York 10016
Principal Investigator: Jennifer Wu, MD
Phone: 212-263-6485
Click here to add this to my saved trials
